-

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

Key Facts

  • Campaign: Project DIY is a new campaign under Aleve’s recently launched Feel Aleve® platform. Project DIY showcases how, when home improvement projects are interrupted by body pain, Aleve delivers up to 12 hours of long-lasting pain relief with just one dose.
  • Talent: HGTV stars Dave and Jenny Marrs, alongside a roster of DIY and home improvement creators.
  • Concept: Show how Aleve helps people manage their pain to stay focused on the projects and passions they love.
  • Hero Activation: Dave & Jenny Marrs lead the renovation of a family's home with the help of Aleve, which provided long-lasting body pain relief.
  • Timing & Channels: The campaign initially launched in May and continues to roll out through summer 2026 across social, digital, and Walmart retail channels.

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Aleve® announced the launch of its Project DIY Campaign, a new DIY-focused marketing initiative under the recently launched Feel Aleve® platform, featuring HGTV stars, Dave and Jenny Marrs. The activation centers around a home transformation project where Dave and Jenny Marrs renovated a family's back porch, taking a non-functioning space and making it into a space the whole family can use and enjoy and bringing to life what it means to Feel Aleve – up to 12-hours of long-lasting body pain relief so you can stay focused on what you love over pain. The initiative began rolling out in May and will continue across social, digital, and Walmart retail channels throughout summer 2026.

In addition to the featured build, the brand is also working with a roster of DIY creators to upgrade their own homes. Through their renovation and home transformation projects, these creators will showcase how Aleve relieves pain and helps power the activities and projects they are passionate about.

“Whether it’s gardening, baking or taking on a DIY project, people want to be able to spend their time doing the things they enjoy and not thinking about pain,” said Lisa Perez, General Manager and VP Marketing at Bayer. “According to Aleve brand insights, 28% of pain relief product buyers consider home improvement projects a hobby, which shows how important these activities can be in people’s lives. Project DIY is about celebrating those passions and showing how Aleve’s long-lasting body pain relief can help people keep doing what they love.”

The Project DIY initiative lives across Aleve-owned and partner channels and includes original social content from Dave and Jenny Marrs, as well as other DIY creators, sharing behind-the-scenes looks at their projects and renovations. Through these real-life stories, the campaign demonstrates how Aleve’s long-lasting body pain relief can help people stay focused on physically demanding projects and spend more time doing the activities they’re passionate about.

“There’s a real sense of accomplishment that comes from transforming a space with your own hands,” said Dave Marrs, Aleve campaign partner and home renovation expert. “For Jenny and me, it was rewarding to take a back porch that wasn’t being used and turn it into a space the whole family can enjoy together. DIY projects can be physically demanding, which is why partnering with Aleve felt like such a natural fit.”

Follow the Campaign:

Follow along via the Aleve social channels, @Aleve_US on Instagram and TikTok.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contacts

Contact for U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

Bayer

GER:BAYN

Release Versions

Contacts

Contact for U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

More News From Bayer

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (CNS) and non-CNS body regions in adult and pediatric patients, including term neonates.1 AMBELVIST is a next-generation mGBCA wit...

Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report to Stefan Oelrich, Member of the Board of Management of Bayer AG and President of the company’s Pharmaceuticals Division. Reinhard follows Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026. “With a compelling performance in recent ye...

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the company’s commitment to continuously adapt and advance its Road to Billions strategy aimed at helping billions of people live healthier lives. As part of these changes, Bayer has appointed new global leaders across the Marketing, Insights &a...
Back to Newsroom